Teriparatide Reference

Educational, not medical advice reference for Teriparatide: Bone, Hormonal; regulatory status, evidence posture, source review, and schedule not…

Plain English

What it is
Teriparatide is a lab-made copy of the active part of a natural hormone your body uses to manage bone (called parathyroid hormone). It is an FDA-approved prescription medicine, sold under the brand name Forteo, given as a shot under the skin.
What people use it for
Doctors prescribe it to treat osteoporosis, which means weak, fragile bones that break easily. It is approved for postmenopausal women and for men who have a high chance of breaking a bone, and for bone loss caused by long-term steroid medicines. Unlike drugs that mainly slow bone loss, it helps the body build new bone. This is a prescription medicine used with medical oversight, not a research or biohacking compound.
What the science shows
The evidence here is strong and based on people, with decades of approved-label use showing it raises bone mass and lowers the chance of fractures. pepSmart shows label-reference information only and is not a tool for measuring out a prescription.
The catch
It is available only by prescription. The label limits how long it can be used over a lifetime, a cap it shares with the similar drug abaloparatide. It can cause blood pressure to drop when standing up, push blood calcium too high, and it is avoided in people who have had radiation to their bones. Common side effects include joint pain, general pain, and nausea.

Reference summary

Teriparatide is a label-verified prescription drug with decades of approved-label osteoporosis evidence. pepSmart surfaces label-reference content only and is not a prescribing tool.

Regulatory and posture

Categories
Bone, Hormonal
Aliases
Forteo, rhPTH(1-34), Parathyroid hormone 1-34
Evidence posture
human
Regulatory status
FDA-approved prescription medication (Forteo). Labeled for osteoporosis treatment in postmenopausal women and men at high risk of fracture, and for glucocorticoid-induced osteoporosis. Cumulative lifetime exposure (teriparatide plus abaloparatide) should not exceed 2 years per label.
Content review status
label verified

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.